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Abstract
Aims: The VALEO® vascular stent is a stainless steel, pre-mounted, open-cell stent. Redilation to large diam-
eters and low profile are advantages in growing children. Clinical experience is scarce. This study aimed to 
analyse our experience with the use of the VALEO® vascular stent in children.
Methods and results: Between June 2010 and December 2012, 41 VALEO® stents were inserted during 
30 transcatheter (group 1) and three perioperative procedures (group 2). Data were retrospectively analysed. 
Median age at implantation was 3.8 years (four days - 23 years), and median weight was 13.3 kg (2.2-53 kg). 
Indications were: pulmonary artery (n=23), pulmonary vein (n=1) or subhepatic vein (n=1) stenosis, and 
ductus arteriosus stenting (n=8). Stent placement was achieved in all but one. Acute complications (n=11) 
included stent dislodgement in two patients and fracture in three patients, with vessel predilatation as a risk 
factor. Median “stent” follow-up reached 7.83 months (0.4-34.3 months) and included 26 recatheterisations 
(23 patients, median interval 6.2 months, range 0.2-33 months). Ten stents were redilated. Surgery in six 
patients (interval 1.9 to 10 months) showed patent endothelialised stents. No “late” type II or III stent frac-
tures were seen.
Conclusions: The VALEO® stent is useful in children. Low radial force is counterbalanced by high flex-
ibility, allowing implantation in distal and tortuous lesions. Early fractures occur. Longer-term follow-up is 
needed.
KEYWORDS
• bare metal stent
• congenital heart 
diseases
• ductus arteriosus
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Introduction
In recent years, stent placement has assumed an important and still 
increasing role in the management of children with congenital heart 
disease. Variety in cell design and material have improved the char-
acteristics of the currently available stents remarkably and made 
their use in children much easier and safer. Stents are currently 
available in various lengths and maximal diameters. Their flexibil-
ity has improved and the pre-mounted stents have better profiles. 
Several stents are redilatable, which allows them to adapt better to 
the growth of the children1,2.
The VALEO® stent (Bard Inc., New Providence, NJ, USA) was 
initially designed for biliary use (VALEO® biliary stent). The use 
of the stent has been extended to atherosclerotic vascular lesions 
(VALEO® vascular stent). It is an open-cell, stainless steel stent, 
pre-mounted on a low-profile, high-pressure balloon. The balloon 
diameters range between 6 and 10 mm (1 mm increments) and the 
stent length between 17 mm (18 mm for the stents mounted on the 
smallest balloons) and 56 mm (17-18, 28, 36 or 56 mm).
The main advantages are the low profile, the flexibility and the 
possibility to dilate the stent to large diameters without shortening3. 
Experience in patients with congenital heart disease, in whom the 
use of this stent is still “off-label”, is scarce3-5. We sought to analyse 
retrospectively our experience with the VALEO® vascular stent in 
growing children with cardiovascular lesions.
Materials and methods
PATIENT POPULATION
Between June 2010 and December 2012, 41 VALEO® stents were 
implanted during 33 procedures in 32 different patients. The pro-
cedure was mostly transcatheter (30 procedures in 29 patients, 
group 1) but in three patients the stent was inserted periopera-
tively (group 2). Median age at the time of stent implantation was 
3.8 years (range 4 days to 23 years), and the median weight was 
13.29 kg (range 2.2 to 53 kg).
Initial cardiac diagnoses, indications for stent placement and 
stent locations are summarised in Table 1.
Pulmonary artery hypoplasia or stenosis (n=23) was the major 
indication. This population included the three patients (two with 
tetralogy of Fallot and one with pulmonary atresia and ventricu-
lar septal defect) in whom the stent was inserted perioperatively 
(group 2).
The second major indication was stenting of the arterial duct as 
part of a hybrid approach for the initial palliation of patients with 
hypoplastic left heart syndrome (HLHS) or “borderline” HLHS, or 
patients with interrupted aortic arch. In our institution, we currently 
favour the hybrid approach (surgical banding of the pulmonary 
arteries and ductal stenting) as initial palliation in patients with con-
firmed or borderline HLHS. Neonates with interrupted aortic arch 
usually undergo primary complete repair but, in the presence of risk 
factors, we also favour a hybrid palliation. The two patients in our 
study with interrupted aortic arch had microdeletion in 22q11. The 
option of primary palliation was taken because of the small weight 
(2.2 kg) for one patient and because of enterocolitis for the other 
one. For logistic reasons the patients first underwent the surgical 
banding of the pulmonary arteries in the operating room and, sub-
sequently, within the following days, ductal stenting was performed 
in the catheterisation laboratory, using femoral venous and arterial 
access.
The patient with pulmonary vein stenosis was a pre-term baby 
with severe bronchopulmonary dysplasia. Cardiac surgery to relieve 
the bilateral pulmonary vein stenosis was contraindicated from a pul-
monary point of view. The patient underwent multiple pulmonary 
vein stenting while on the waiting list for heart-lung transplantation.
TRANSCATHETER STENT INSERTION (GROUP 1, N=30)
Informed consent of the parents and/or patients was always obtained. 
Catheterisation was performed under general anaesthesia in all 
patients. Venous and arterial access was obtained, according to the 
planned procedure. The venous access was usually femoral. In three 
patients with cavopulmonary shunt, jugular venous access was man-
datory in order to reach the pulmonary arteries. In one patient, the 
jugular venous access was chosen as femoral venous access failed. 
Table 1. Patients’ characteristics at time of initial stent implantation.
N Location of stent Reason for stent Initial diagnosis Median age Median weight
23 Pulmonary artery Pulmonary stenosis and/
or hypoplasia
N=10 (9 patients): Patr VSD 
(rehabilitation programme)
N=4: Tetralogy of Fallot
N=1: SV+Patr
N=2: TGV
N=2: Other SV
N=1: Arterial tortuosity syndrome
N=2: Diffuse PA branch stenosis
N=1: Critical PS, RPA stenosis post 
Blalock shunt
2.98 yrs
(7 mo-23 yrs)
12 kg
(6.5–50 kg)
8 Arterial duct Hybrid approach N=2: Interrupted aortic arch
N=6: Hypoplastic left heart syndrome or 
“borderline HLHS”
17 days
(4-25 days)
3 kg
(2.2–3.9 kg)
1 Pulmonary vein Pulmonary vein stenosis Multiple PV stenosis 3.8 yrs 12.8 kg
1 Subhepatic vein Subhepatic vein stenosis 2.5 yrs 10.4 kg
HLHS: hypoplastic left heart syndrome; PA: pulmonary artery; Patr: pulmonary atresia; PS: pulmonary stenosis; PV: pulmonary vein; RPA: right 
pulmonary artery; SV: single ventricle; TGV: transposition of the great arteries; VSD: ventricular septal defect
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Transhepatic venous access was elected in the patient with hepatic 
vein stenosis. All patients received heparin (100 U/kg) once venous 
and arterial access had been obtained. Heparin (50 U/kg) was 
repeated after two hours if needed. Haemodynamic and angiographic 
assessments, as needed for the procedure, were first obtained.
In case of vessel stenosis (pulmonary artery, pulmonary vein, 
subhepatic vein) the vessel was predilated if needed, according to 
the operator’s clinical judgement. Predilation was performed with 
medium-, high- or ultra-high-pressure balloons. The stent length 
and the balloon size were chosen according to the usual rules, in 
order to normalise as much as possible the vessel diameter, avoid-
ing overdilation of the vessel. The length of the stent was chosen 
according to the total length of the stenosis or hypoplasia, even if 
this implied covering of side branches. A long sheath was advanced 
up to the stenosed vessel, in order to protect the balloon-stent 
ensemble. The smallest possible long sheath diameter was always 
chosen (6 or 7 Fr), according to the manufacturer’s recommenda-
tions. In a few very small patients with very high right ventricular 
pressures, it was deliberately decided not to use a long sheath in 
order to minimise haemodynamic compromise. The stent was in 
those cases advanced “unguarded” over the wire. Post-dilation of 
the stent was performed if there was residual stenosis or if the wall 
apposition of the stent was considered insufficient.
In case of ductal stenting (hybrid approach) the prostaglan-
din infusion was usually stopped four to eight hours before the 
expected start of the procedure. Aortography was first performed 
to analyse the morphology of the duct and the size of the descend-
ing aorta. The stent length was in these cases always 17/18 mm for 
short ducts and 26 mm for longer ducts. The diameter of the bal-
loon was chosen to fit the diameter of the descending aorta. A wire 
was first inserted in an anterograde way through the duct. The wire 
was in some cases snared at its distal aortic end to increase stability. 
The pre-mounted stents were advanced over the wire without the 
use of a long sheath in order to minimise the haemodynamic inter-
ference in these very unstable children. Particular care was taken 
to advance the balloon-stent ensemble at the level of the tricuspid 
valve to avoid dislodgement at this level.
SURGICAL STENT INSERTION (GROUP 2)
Informed consent of the parents and/or patients was always 
obtained. The stent placement was performed under cardiopulmo-
nary bypass, as part of the total repair for two patients with tetral-
ogy of Fallot and at the time of conduit change in one patient with 
Patr VSD. Stent selection (balloon diameter and length of the stent) 
was based on preoperative CT-scan or angiographic assessment. 
The stents were directly implanted without fluoroscopy guidance. 
Also, they were always secured by the surgeon with a single proxi-
mal stitch and flared at their proximal end.
DATA ANALYSIS AND STATISTICS
Patients’ clinical data, procedural characteristics, complications and 
follow-up data were retrospectively analysed. Follow-up was based 
on the clinical judgement of the attending paediatric cardiologists. 
Full clinical assessment, ECG and echocardiography were regularly 
performed in most patients. CT scan and repeat cardiac catheterisa-
tion were performed when indicated, based on clinical and echocar-
diographic evolution and according to the initial treatment strategy.
For the patients in whom the stent was inserted with the aim of 
remaining “permanently” (e.g., pulmonary arteries), the date of the 
latest clinical assessment was considered as the latest follow-up. 
For the patients who had ductal stenting (hybrid approach), the date 
of surgical treatment with arch reconstruction or the date of death, if 
before surgery, was used (“stent” follow-up). The date of the heart-
lung transplant was used for the patient with multiple pulmonary 
vein stenosis.
Univariate analyses were performed using the chi-squared test 
(or Fisher’s exact test if necessary) to test relationships between 
qualitative variables. Multivariate analyses were performed using 
logistic regression models to assess factors associated with acute 
complications. All analyses were performed using R3.1 software 
(Copyright (C) 2013 The R Foundation for Statistical Computing, 
Vienna, Austria).
Results
ACUTE PROCEDURAL RESULTS
Predilation of the lesion was performed in 14 out of the 33 pro-
cedures (42%). One predilation was on a pulmonary vein stenosis 
and the remaining 13 on pulmonary arteries. The selected stents 
had balloon diameters ranging between 6 and 10 mm. The initial 
stent length was 17/18 mm (n=23), 26 mm (n=17) or 36 mm (n=1). 
For the eight patients in whom stents were inserted in arterial ducts 
(hybrid procedures), the length was 17/18 mm in four patients and 
26 mm in the four other patients. The VALEO® stents could be 
implanted in all except one patient. This patient had arterial tortuos-
ity syndrome characterised by severe hypoplasia, stenosis and tor-
tuosity of the pulmonary arteries that made it impossible to advance 
and deploy the stent properly, despite the use of a guiding cath-
eter. The guiding catheter could not cross the lesion and, while try-
ing to advance the pre-mounted stent through the very narrow and 
tortuous vessel, the stent slid from the balloon and could not be 
placed correctly in the pulmonary artery. This stent could however 
be secured and finally deployed in the inferior vena cava (Figure 1). 
In seven patients, two VALEO® stents were implanted, most often 
in different locations. In six patients, other additional stents were 
inserted, either in side branches or in other locations. This includes 
a covered stent inserted in one patient after dissection was noticed 
after the VALEO® stent deployment. The open-cell design of the 
VALEO® stent allowed easy implantation of other stents across the 
cells (Figure 2). Vessel expansion was considered sufficient in most 
cases and post-dilation was only performed in five cases (all PAs).
COMPLICATIONS
Acute complications occurred in 33% (11/33) of the procedures 
and were as follows: one reperfusion syndrome, three cases of 
haemoptysis, two cases of transient low cardiac output (including 
one patient who had concomitant open heart surgery), three stent 
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fractures and two stent dislodgements. All the complications were 
seen in the PA group.
One stent fracture occurred in a very stenosed RPA in a patient 
with Patr VSD who previously had a right modified Blalock-
Taussig shunt inserted. The stenosis was resistant and predilated 
with an ultra-high-pressure balloon. The stent fracture was noticed 
immediately following stent implantation. Small wall dissection 
and aneurysm formation were noticed and required covered stent 
implantation with subsequent satisfactory angiographic appear-
ance. The other fracture occurred in a patient born with DORV and 
pulmonary atresia presenting conduit and proximal RPA stenosis. 
The VALEO® stent mounted on an 8 mm balloon was inserted in 
the proximal RPA without difficulties. Despite a good result, the 
stent was noticed to be fractured, without dissection or significant 
obstruction. The third stent fracture occurred in a surgical patient 
(group 2) at the time of postoperative stent dilation. The stent frac-
ture was not associated with obstruction or vessel damage and was 
left untreated.
One stent dislodgement, which occurred in a patient with arte-
rial tortuosity, has been described earlier. The other dislodgement 
occurred in a patient with Williams-Beuren syndrome with severe 
hypoplastic pulmonary arteries and suprasystemic right ventricular 
pressures. The choice was made not to advance a long sheath to 
Figure 1. Angiographies in a patient with arterial tortuosity 
syndrome in whom we planned to implant a VALEO® stent in the 
right pulmonary artery. The left panel (A) shows the very stenosed 
and tortuous right pulmonary artery in which the stent could not be 
advanced. The stent was finally deployed in the low IVC (B).
Figure 2. Proximal left and right pulmonary stenosis. A) A VALEO® 
stent is first inserted across the proximal LPA stenosis. The stent 
protrudes in the MPA and jails the RPA. The second stent (maxi-LD 
stent) is delivered into the proximal RPA, across a predilated cell of 
the VALEO® stent (B). Final result is shown on the right panel (C).
reduce the haemodynamic compromise. However, the stent slipped 
from the balloon at the level of the tricuspid valve. The stent could 
not be retrieved. It was first decided to expand the stent slightly at 
the tricuspid level, towards the apex of the RV, which then allowed 
the advancement of a long sheath and deployment of other stents in 
the distal pulmonary arteries with subsequent significant reduction 
in the right ventricular pressures. The stent captured in the tricuspid 
valve was surgically removed, without any need for valve repair.
Reperfusion syndrome, haemoptysis and low cardiac output 
(6/33, 18%) were thought to be “disease-related” and indicated 
the severity of the pulmonary artery abnormalities. The stent frac-
tures and stent dislodgements (5/33, 15%) were considered “stent-
related” complications. Complications were more frequently seen 
in patients who required predilation of the pulmonary arteries. The 
relationship between predilation and complication was signifi-
cant in the pulmonary artery group in univariate analysis (p<0.05). 
Multivariate analysis failed to show any significant risk factor.
FOLLOW-UP DATA
All patients were treated with IV heparin or low molecular weight 
heparin at least during the first 24 hours following stent insertion. 
This was changed for aspirin (5 mg/kg) as soon as possible. Aspirin 
was maintained for at least six months or until stent removal (hybrid 
procedures).
Four patients died, all with hypoplastic left heart syndrome 
(hybrid approach), before the second stage surgery, as a result 
of right ventricular failure. “Stent follow-up”, as defined earlier, 
reached a median of 7.83 months (range 0.4 to 34.3 months) for the 
whole cohort. For the PA group alone, follow-up reached a median 
of 13.4 months (range 3.7 to 34.3 months).
During follow-up, a total of 26 catheterisations were performed 
in 23 patients (72%). The first recatheterisations (n=23) were per-
formed a median of 6.2 months (range 0.2-33 months) after VALEO® 
stent implantation. This includes the three patients from group 2, for 
whom it was decided to perform a cardiac catheterisation electively 
within the first months following surgery. The indications for recath-
eterisation in the other patients were either preoperative assessment, 
or based on echocardiographic data (increase of RV pressures) and/or 
lung-perfusion scan data or finally as part of the rehabilitation strat-
egy in pulmonary atresia patients. One patient in the surgical group 
had one additional catheterisation 11 months after the first one. One 
other patient had two other cardiac catheterisations as part of a reha-
bilitation programme, 8.5 months and 13 months, respectively, after 
the initial VALEO® stent implantation.
In the three patients from group 2, further balloon dilation of the 
stent was performed to improve wall apposition. This resulted in 
acute fracture of the stent in one patient. This patient was recath-
eterised 11 months later and the stent redilated without any acute 
problem, in order to catch up with growth.
In one patient with borderline hypoplastic left heart syndrome, 
the VALEO® stent had completely closed off due to intense inti-
mal proliferation. This could be explained by progressive evolution 
towards a biventricular circulation and “functional” exclusion of 
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the arterial duct. Nevertheless, the child had persistent post-cap-
illary pulmonary hypertension and finally underwent a successful 
Norwood-Sano intervention. Four other patients presented sig-
nificant intimal proliferation of the stent and needed redilatation 
(Figure 3). Two other patients had redilatation of their stent to catch 
up with growth. In all the other patients, the VALEO® stent was 
nicely patent and did not need reintervention. The redilations of the 
VALEO stents were all performed with medium- or high-pressure 
balloons and with diameters at the most 2 mm larger than the initial 
balloon diameter. None of the stents has so far been dilated up to 
a large diameter (>15 mm).
Figure 3. Lateral angiographies in a stented left pulmonary artery. 
Panel A shows mild endothelial proliferation at the proximal end of 
the stent (white arrow). The proliferation might have been favoured 
by mild residual stenosis at mid-stent level. Panel B shows good 
response after balloon dilation.
Figure 5. Chest x-ray showing how difficult it is to ascertain absent 
or present fracture on a simple chest x-ray.
Figure 4. Fluoroscopic and macroscopic aspects of stents inserted in 
a left pulmonary vein. The left panel shows the VALEO stent (white 
arrow) inserted in the left lower pulmonary vein (A). The right panel 
(B) shows the explanted lungs with the VALEO stent in the vein 
(white arrow) nicely patent.
Six patients had surgery performed which allowed visualisation 
of the stent. In five, the stent was correctly endothelialised and pat-
ent (Figure 4). The remaining patient was the one described above 
with complete occlusion of the stent due to functional exclusion of 
the ductus.
Discussion
The ideal stent for use in growing children is still unavailable. To 
reach perfection, stent characteristics should associate low profile, 
high flexibility, durability, radial force and strength and have the pos-
sibility to be dilated to large diameters. The spectrum of lesions to 
stent in patients with congenital heart defects is however very large. 
The ideal stent for treatment of coarctation in a teenager will be differ-
ent from the ideal stent for tortuous arterial duct stenting in a newborn. 
The paediatric and congenital interventional cardiologist will need 
a “range” of stents on the shelf to face different clinical situations1.
The VALEO® stent is a balloon-expandable stent mounted on 
a low-profile flexible angioplasty balloon, initially designed for bil-
iary use. The stent is laser cut into a 316 L stainless steel tube, using 
an open lattice design. The open-cell design is responsible for very 
limited foreshortening if the stent is dilated progressively3. The major 
advantages of the pre-mounted VALEO® stent in children are the low 
profile, the flexibility, the open-cell design that facilitates further 
access and treatment of side branches, and the potential for further 
dilation up to large diameters without shortening. These advantages 
are all illustrated in our study. The low profile and high flexibility 
were very advantageous in our small patients and in the small ves-
sels. The open-cell design allowed access and treatment of other side 
branches or of the contralateral pulmonary artery in some patients. 
Redilatation of the stent has been successfully performed in a few 
patients but our study follow-up is too short to analyse long-term 
redilatation possibilities in growing children properly. In addition, 
none of the stents has so far been dilated to a large diameter (>15 mm). 
We used the stent in various locations, and this versatility of the stent 
may be an advantage for paediatric units which have a limited access 
to the stents that are currently available on the market.
Stents with open-cell design are considered to have lower radial 
force than stents with closed-cell design. In our population, charac-
terised by young age and the variety of diseases, the stent was able 
to open up the lesions in an adequate way with sustainable results at 
follow-up. It is, however, important to note that most of the patients 
During follow-up, 27 patients (84%) had chest x-ray, fluoros-
copy (cardiac catheterisation) or CT scan performed. None of 
the patients presented “late” type II or type III fractures. Type I 
fractures were very difficult to recognise or to rule out, due to the 
design of the stent cells (Figure 5).
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Impact on daily practice
Stent placement in young and small children is a challenge. 
Stents don’t grow and the material is not perfectly adapted to 
small vessels or small hearts. Once a stent is placed in a grow-
ing child we know that further interventions will be required to 
match the growth. Stents such as the VALEO stent have a low 
profile and are redilatable to large diameters. Their implantation 
is easy and safe even in very small children. These arguments 
allow us to consider their use to enlarge vessels in small chil-
dren, whenever other therapies are not suitable.   
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with tight pulmonary artery lesions had the lesions “prepared” 
before stent insertion using medium- or high-pressure balloons, 
as part of intense pulmonary artery rehabilitation programmes in 
patients with very abnormal pulmonary arteries6,7.
Two stent dislodgements were encountered in our study, both in 
patients with difficult pulmonary artery lesions. This suggests that 
the stent is not reliably mounted on the balloon. Although we have, 
in our unit, advanced the stents “unprotected” (without the use of 
a long sheath) in some circumstances such as ductal stenting in neo-
nates (hybrid approach) and in case of very high right ventricular 
pressures, this is something that we do not recommend any longer. 
The stent needs to be advanced inside a long sheath to secure the 
balloon-stent ensemble and to check stent position with angiogra-
phy before implantation.
Fractures were seen in at least three stents (7%). In one patient, 
the fracture was associated with a small vessel dissection, while 
in the two other cases the fracture was not associated with vessel 
obstruction, vessel damage or loss of stent integrity. Proper diagno-
sis of fractures requires fluoroscopic analysis, which was only done 
during follow-up in the patients who had repeat catheterisation. 
This means that additional type I fractures may have been missed. 
However, no type II or type III fractures were detected8. Stent frac-
tures are usually rare in locations other than right ventricular out-
flow tracts. Although our study is very small, our incidence of stent 
fracture seems to be higher than the one reported with other stents9. 
This might be a correlate of high flexibility, open-cell design and 
limited number of struts. Because of the stent fragility, we would 
not recommend the use of this stent in infants with tetralogy of 
Fallot to open up very stenotic right ventricular outflow tracts.
Our study has several limitations. It is a retrospective study. It 
includes a broad spectrum of diseases and lesions. No precise haemo-
dynamic or angiographic parameters could be analysed and com-
pared to show haemodynamic and angiographic efficacy. Despite 
these limitations, our study gives a good overview of the possible 
applications, benefits and limits of the VALEO® stent in children.
Conclusions
We summarise and analyse our initial experience with a stent origi-
nally not designed for paediatric cardiac use. So far, it is the largest 
study analysing the use of the VALEO® stent in congenital heart 
disease. In our hands, the stent has been useful because of its low 
profile, its flexibility, the open-cell design and the possibility to 
redilate the stent further. We have, however, limited its use to “low-
pressure” lesions (such as arterial ducts) or predilated “higher-
pressure” lesions. It is not a robust stent and fractures do occur, 
probably at a higher incidence than with the other available stents. 
Because of the open-cell design it is difficult to diagnose these strut 
fractures, and longer follow-up is required. Stent dislodgement is 
possible and we strongly discourage advancing it without a long 
sheath. Longer follow-up is required.
